Charles River Laboratories heads into mid-June with an interesting split: a high-profile analyst upgrade landed this morning, even as short sellers have been steadily rebuilding positions over the past two weeks.
The analyst story is the clearest catalyst of the week. Morgan Stanley's Ricky Goldwasser upgraded CRL to Overweight from Equal-Weight this morning — a move that matters given the firm's weight in the sector — lifting her price target to $220 from $185. That puts the new target roughly 19% above the current price of $184.79. The upgrade follows a similar move from CLSA late last month, which shifted to Outperform with a target of $219. Together, the two upgrades pull consensus firmly toward the bullish camp: four Outperform-or-equivalent ratings against two Holds, with the mean Street target at $214.60. Barclays and Evercore both nudged targets higher after Q1 results in May. The lone dissent is JP Morgan, which stayed Neutral with a $160 target — a meaningful gap from the pack — and is the clearest expression of bear-side caution on the name.
The bull case rests on recovery. CRL's Q1 print was weak — the stock fell roughly 2% on the day and shed a further 12% over the following five sessions, pressured by staffing headwinds and soft client drug-development spending. But the 22% rebound over the past month suggests the worst-case scenario has been priced out, and the Morgan Stanley upgrade signals at least one bellwether firm now believes the earnings trough is visible. Valuation backs that thesis: the PE multiple has expanded by nearly 2.9x over 30 days to just under 16x, and the EV/EBITDA of 11.2x is ticking lower even as the stock recovers, implying margin-of-safety improvement. The analyst recommendation divergence factor ranks in the 92nd percentile — an unusually wide spread between bulls and bears by historical standards.
Short positioning tells a more complicated story. SI has climbed roughly 12% over the past week to 8.4% of the free float — a material move that has accelerated since early June. Looking at the history, around 3.7 million shares were short at the start of June; that figure has since grown to 4.15 million. The borrow market, however, remains entirely loose. Availability is running at roughly 498% — meaning there are five shares available to lend for every two already borrowed — and cost to borrow is a negligible 0.41%, down from already-low levels a month ago. That combination tells a specific story: shorts are adding exposure, but there is no squeeze dynamic and no particular stress in the lending pool. This looks like deliberate fundamental positioning rather than forced covering risk.
Options positioning adds a contrarian wrinkle. The put/call ratio has dropped to 0.27, more than one standard deviation below its 20-day average of 0.33 — the lowest reading in recent weeks and close to the 52-week low of 0.22. That means call buying is running well ahead of put buying, a markedly bullish posture in the options market. It sits in sharp contrast to the short-side rebuild: options traders are leaning into the upgrade story; short sellers are not fully convinced. The divergence between these two groups is the defining tension in CRL positioning right now.
The next scheduled catalyst is earnings on August 5. The recent print pattern — down 2% on the day, down 12% over five sessions — will keep that date on the radar. With the Street increasingly aligned on recovery, the August print becomes less about whether the Q1 miss was a one-off and more about whether client spending trends have genuinely stabilised. The pace of short interest growth between now and then is the number to watch.
See the live data behind this article on ORTEX.
Open CRL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
